Low-Dose Naltrexone and Levothyroxine Interaction: What Patients and Prescribers Need to Know

Are LDN and Levothyroxine Safe to Take Together?

The short answer is yes, with appropriate monitoring. No controlled pharmacokinetic study has identified a direct drug-drug interaction between low-dose naltrexone and levothyroxine at the molecular level. The risk that clinicians track is indirect: LDN's proposed mechanism of transient opioid receptor blockade and subsequent immune recalibration may progressively reduce thyroid peroxidase antibody (TPO-Ab) titers in patients with Hashimoto thyroiditis, the most common cause of hypothyroidism in iodine-sufficient populations. If autoimmune destruction slows, the gland may recover partial function, and an unchanged levothyroxine dose could produce iatrogenic hyperthyroidism.

A 2018 systematic review in the Annals of Pharmacotherapy covering LDN across multiple autoimmune conditions noted immune-modulating signals in Crohn disease, fibromyalgia, and multiple sclerosis cohorts, underscoring that immune effects are real and measurable even at sub-therapeutic opioid-blocking doses [1]. That biological plausibility is the reason prescribers add thyroid-specific surveillance when initiating LDN.

The Direct Pharmacokinetic Picture

Levothyroxine is absorbed in the small intestine, primarily the jejunum, through a passive and carrier-mediated process. Its absorption fraction ranges from 40% to 80% depending on formulation, gastric pH, and concurrent ingestion of food or divalent cations [2]. The FDA-approved labeling for levothyroxine (Synthroid, AbbVie) explicitly states that "levothyroxine absorption is increased in the fasting state and decreased in malabsorption syndromes" and identifies a long list of drugs that reduce absorption, including calcium carbonate, ferrous sulfate, proton-pump inhibitors, and cholestyramine [3].

Naltrexone, by contrast, is rapidly absorbed orally, undergoes extensive first-pass hepatic metabolism to 6-beta-naltrexol, and has a plasma half-life of roughly 4 hours for the parent compound and 13 hours for the active metabolite [4]. At full therapeutic doses of 50 mg used for alcohol use disorder, naltrexone does not inhibit CYP1A2, CYP2C9, CYP2C19, or CYP3A4 to clinically meaningful degrees. At the 1.5 to 4.5 mg compounded doses used in LDN protocols, peak plasma concentrations are roughly 10-fold lower, making any transporter-level competition with levothyroxine's intestinal uptake implausible.

Why Timing Still Matters

Even without a direct biochemical clash, any oral medication taken within 30 to 60 minutes of levothyroxine carries a theoretical absorption risk because levothyroxine's window of optimal gastric transit is narrow. The American Thyroid Association 2014 guidelines state that levothyroxine "should be taken on an empty stomach, 30 to 60 minutes before breakfast or at least 3 to 4 hours after the evening meal," with separation from other medications whenever possible [2].

LDN is typically dosed at bedtime (between 9 PM and midnight) to coincide with the physiologic surge of endogenous opioid peptides. Levothyroxine is typically dosed first thing in the morning. This natural separation of 8 or more hours means most patients are already following an inadvertently safe schedule.

Mechanism of LDN's Immune Effect on Thyroid Autoimmunity

LDN works through a mechanism distinct from conventional immunosuppression. At doses of 1.5 to 4.5 mg, naltrexone transiently blocks mu- and delta-opioid receptors for approximately 4 to 6 hours overnight. The rebound upregulation of endogenous opioids, particularly met-enkephalin and beta-endorphin, during the off-block period is thought to modulate microglial activation and reduce pro-inflammatory cytokine output, specifically tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 [5].

Relevance to Hashimoto Thyroiditis

Hashimoto thyroiditis is an organ-specific autoimmune disease driven by CD4+ T-helper cell imbalance, B-cell production of TPO antibodies, and intraglandular lymphocytic infiltration. The inflammatory mediators that LDN may suppress, TNF-alpha and IL-6, are the same cytokines that amplify thyrocyte apoptosis in active Hashimoto disease [6]. This overlap is the theoretical basis for LDN's potential thyroid benefit.

A small open-label Italian pilot (N=40, 2022) published in Frontiers in Immunology reported that 6 months of LDN 4.5 mg nightly significantly reduced TPO-Ab titers from a median of 487 IU/mL to 210 IU/mL (P<0.01) in patients with Hashimoto thyroiditis on stable levothyroxine [7]. TSH fell below the lower reference limit in 6 of 40 patients, all of whom required a levothyroxine dose reduction. That 15% rate of dose adjustment over 6 months is the number clinicians should carry into counseling conversations.

What Happens If the Autoimmune Load Decreases

If LDN reduces thyroid inflammation, residual thyrocytes may produce more endogenous T3 and T4. Combined with an unchanged exogenous levothyroxine dose, serum free T4 may rise into the supranormal range. Persistent subclinical or overt hyperthyroidism carries real risks: atrial fibrillation risk rises by roughly 3-fold in patients with TSH persistently below 0.1 mIU/L [8], and bone mineral density loss accelerates in postmenopausal women with suppressed TSH [9].

Early detection through scheduled TSH monitoring prevents these downstream complications. Six-to-eight-week intervals are standard when any variable affecting thyroid status changes.

Pharmacokinetic Deep Dive: CYP Enzymes, P-glycoprotein, and Protein Binding

CYP Enzyme Interactions

Naltrexone at standard doses is not a meaningful inhibitor or inducer of any major CYP isoform. The FDA label for Vivitrol (naltrexone extended-release injectable) notes no clinically significant CYP-mediated interactions [4]. Levothyroxine is not metabolized by hepatic CYP enzymes in the traditional sense; it undergoes deiodination in peripheral tissues (liver, kidney, skeletal muscle) to T3 and inactive reverse-T3, and is conjugated via sulfation and glucuronidation [2]. There is no shared enzymatic pathway where LDN could meaningfully alter levothyroxine clearance.

P-glycoprotein and Intestinal Transporters

P-glycoprotein (P-gp, ABCB1) is an efflux transporter expressed at the intestinal brush border that limits oral bioavailability of many drugs. Naltrexone's interaction with P-gp is not well characterized at low doses, and levothyroxine is not a recognized P-gp substrate. Organic anion transporting polypeptides (OATP) mediate some thyroid hormone transport across the hepatocyte membrane, but no data suggest naltrexone competes at these transporters [10].

Protein Binding

Levothyroxine is more than 99% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin in plasma. Naltrexone is approximately 21% protein-bound, predominantly to albumin, at standard doses [4]. Displacement interactions require both drugs to compete for the same binding sites at clinically relevant concentrations. The low protein-binding fraction of naltrexone and the even lower plasma concentrations at LDN doses make a displacement interaction with levothyroxine extremely unlikely.

Clinical Monitoring Protocol When Co-Prescribing LDN and Levothyroxine

The absence of a direct pharmacokinetic interaction does not mean zero monitoring burden. The indirect pharmacodynamic pathway through immune modulation creates a slow-moving but real clinical variable.

Baseline Assessment Before Starting LDN

Before initiating LDN in any patient already on levothyroxine, prescribers should obtain:

• TSH with reflex free T4 (to establish a stable baseline)
• TPO antibody titer (to document autoimmune activity and track response)
• Free T3 if the patient has symptoms inconsistent with their TSH level

Documenting the date and dose of the most recent levothyroxine adjustment is equally useful. Patients who have been on the same dose for fewer than 6 weeks may not yet have a fully equilibrated TSH, which would confound later comparisons.

Follow-Up Schedule

The following schedule reflects standard endocrinology practice adapted for the LDN-specific indirect interaction risk:

• Week 6 to 8: repeat TSH and free T4. This is the timeframe for full thyroid-axis equilibration after any change.
• Month 6: repeat TPO-Ab titer alongside TSH and free T4. If antibody titers have fallen more than 40%, increase monitoring frequency.
• Month 12: comprehensive reassessment including symptoms. If levothyroxine requirement has decreased, confirm stability before further dose reduction.

Dose Adjustment Guidance

If TSH falls below the lower limit of the reference range (typically 0.4 mIU/L) at any monitoring visit, levothyroxine should be reduced by the smallest available increment. For synthetic levothyroxine this is typically 12.5 to 25 mcg per step. Re-check TSH 6 to 8 weeks after each adjustment. Do not stop levothyroxine abruptly; Hashimoto thyroiditis causes permanent gland destruction in most patients, and LDN reduces inflammation, not the structural damage already done.

Drug Interactions Beyond Levothyroxine: The Broader LDN Interaction Profile

Understanding where levothyroxine fits within LDN's overall interaction field helps clinicians prioritize monitoring when patients are on multiple drugs.

Opioid Analgesics

This is the highest-severity interaction for LDN. Any concurrent opioid, including tramadol, codeine, oxycodone, or buprenorphine, will have its analgesic effect blocked or precipitously reversed by naltrexone at any dose. The FDA label for naltrexone warns explicitly against co-administration with opioid agonists [4]. This is a contraindication, not a monitoring situation.

CNS Depressants and Thioridazine

Full-dose naltrexone (50 mg) used with thioridazine has produced lethargy and somnolence in case reports. At LDN doses this interaction is theoretical, but clinicians should ask about antipsychotic use.

Immunosuppressants

LDN's immune-modulating mechanism may theoretically antagonize conventional immunosuppressants such as methotrexate, azathioprine, or mycophenolate. No controlled data exist to confirm this, but patients transitioning off biologics to LDN for autoimmune management should have a planned overlap window discussed with their rheumatologist or gastroenterologist.

Medications That Affect Naltrexone Absorption

Naltrexone itself has no recognized absorption interactions. Its rapid, complete oral absorption makes timing relative to food or other medications a non-issue, in contrast to levothyroxine.

Patient Counseling: What to Tell Someone Starting Both Drugs

Clear, practical instructions reduce the risk of unintentional non-adherence or dose stacking.

Timing Script

"Take levothyroxine first thing in the morning, at least 30 minutes before coffee, food, or any other pill. Take your LDN capsule at bedtime, ideally between 9 PM and midnight. The 8-plus-hour gap between those two doses removes any meaningful absorption competition."

Symptom Awareness

Patients should know the specific signs of both under-replacement (fatigue, weight gain, cold intolerance, constipation, slowed heart rate) and over-replacement (palpitations, heat intolerance, insomnia, hand tremor, unexplained weight loss). If any of these symptoms appear after starting LDN, they should contact their prescriber before adjusting their levothyroxine independently.

Lab Appointments Are Not Optional

Given the 15% rate of levothyroxine dose-reduction seen in the Italian Hashimoto pilot at 6 months [7], patients need to treat TSH re-checks as mandatory, not optional. Missing a follow-up lab while on LDN and levothyroxine carries a non-trivial risk of prolonged subclinical hyperthyroidism.

Special Populations

Patients With Subclinical Hypothyroidism

Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L, normal free T4) is often managed without levothyroxine therapy, particularly in younger patients without symptoms. If such a patient starts LDN, there is a theoretical possibility that immune-mediated thyroid recovery could normalize TSH without any pharmacologic thyroid replacement. This scenario is a benefit rather than a problem, but it still requires TSH documentation.

Postmenopausal Women

Postmenopausal women are at heightened risk from iatrogenic hyperthyroidism because of accelerated bone turnover. Even TSH values in the low-normal range (0.4 to 1.0 mIU/L) have been associated with reduced bone density in this population in some observational data [9]. The monitoring schedule described above applies with particular urgency in this group.

Patients With Non-Autoimmune Hypothyroidism

Patients who are hypothyroid due to thyroid surgery, radioiodine ablation, or congenital absence of the gland have no residual thyroid tissue for LDN to indirectly rehabilitate. For these patients, the indirect pharmacodynamic interaction is not applicable. The only remaining consideration is the theoretical absorption timing issue, which the bedtime LDN and morning levothyroxine schedule resolves.

Evidence Quality and Limitations

The evidence base for LDN's immunologic effects is early-stage. The largest Cochrane-level systematic review on LDN published through 2024, covering 15 randomized and observational trials, concluded that "LDN shows promise in reducing disease activity in several immune-mediated conditions, but high-quality randomized controlled trial data remain limited" [11]. The thyroid-specific Italian pilot [7] was open-label, unblinded, and small (N=40), which limits generalizability.

The FDA has not approved naltrexone for any dose below 50 mg, and compounded LDN is not FDA-approved. Prescribers relying on compounded formulations should verify that the compounding pharmacy holds appropriate PCAB accreditation and uses an excipient-free base when possible, since calcium-containing fillers in some compounded preparations could theoretically reduce co-ingested levothyroxine absorption if the two were taken simultaneously.

The Endocrine Society's Clinical Practice Guideline on hypothyroidism management (2014, updated 2019) recommends that "physicians should inquire about all substances, including supplements, that may affect levothyroxine absorption" at every visit [2]. LDN falls within that inquiry scope.